INTRODUCTION {#sec1-1}
============

Morbihan syndrome is a rare entity characterized clinically by chronic erythematous edema localized exclusively on the forehead, glabella, eyelids, and cheeks. It is considered a clinical variety or a complication of acne or rosacea. Caucasian adults of both sexes are affected. Neither laboratory nor instrumental abnormalities are observed. The histopathological picture is aspecific. Oral isotretinoin is considered the therapy of first choice, although not all patients improve.

We present a typical, although severe, case of Morbihan syndrome.

CASE REPORT {#sec1-2}
===========

A 60-year-old Caucasian man was admitted to our Department because of a dermatitis on the face. The patient stated that he was in good general health, except for obesity (120 kg), and that he was not in therapy with systemic drugs. The patient also stated that the dermatitis appeared approximately 4 years before and that it was unsuccessfully treated with oral corticosteroids.

Dermatological examination revealed a severe erythematous edema involving the forehead, glabella and both eyelids, because of which the patient was not able to open his eyes completely. Furthermore, erythema and telangiectasiae were visible on the nose and cheeks \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].
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General physical examination did not reveal anything pathological.

All laboratory and instrumental examinations (echography of periorbital area, carotids, and thyroid, chest X-rays, electrocardiogram, echocardiogram, and echography of the abdomen) were within normal ranges or negative.

Histopathological examination showed dermal edema, perivascular and periadnexal lympho-histiocytic infiltrate, and sebaceous gland hyperplasia. No mast cells were observed.

A diagnosis of Morbihan syndrome was made.

The patient was treated with oral isotretinoin \[starting daily dosage: 0.5 mg/kg (=60 mg/day) for 4 weeks)\]. Maintenance dosage was 0.5 mg/kg/day for 22 weeks. Only a mild increase in total cholesterol levels was recorded. No significant clinical improvement was observed.

DISCUSSION {#sec1-3}
==========

Morbihan syndrome was possibly first described in 1956 by Schimpf,\[[@ref1]\] who published four case reports on this subject from 1956 to 1960.\[[@ref2]--[@ref4]\] Unfortunately, none of these articles had any clinical photographs. Furthermore, the histopathological picture of these patients was characterized by granulomas, that are rarely present in Morbihan syndrome. In 1972, Merklen, *et al*.\[[@ref5]\] named this entity as "infiltration massive persistante du front avec fort œdème palpébral," i.e., massive persistent infiltration of the forehead with severe edema of the eyelids. In 1991, Gorin, *et al*.\[[@ref6]\] named this entity as Morbihan disease. This name was due to the fact that the first French patient was observed in 1957 by Degos in a farmer who came from the region of Morbihan (North-Western France). However, we do believe that the name of "Morbihan syndrome," in consideration of possible different etiopathogenetic factors, is more correct.

Caucasian adults of both sexes are affected: To our knowledge, only one black\[[@ref7]\] and one Indian\[[@ref8]\] patient were reported.

Morbihan syndrome is characterized clinically by the slow appearance of erythematous edema localized exclusively on the forehead, glabella, eyelids, and cheeks. The consistency of edema is solid. The patients complain of no symptoms.

Etiopathogenesis of Morbihan syndrome is not completely known. According to most of the authors, it is a clinical variety or a complication of acne\[[@ref9]\] or rosacea.\[[@ref10]\] In our patient, the age, the clinical picture (erythema and telangiectasiae on the nose and cheeks), as well as the histopathological picture (sebaceous gland hyperplasia), support a correlation with rosacea. Furthermore, according to some authors, Morbihan syndrome may be caused by lymph vessel abnormalities.\[[@ref11][@ref12]\]

Laboratory and instrumental examinations were always negative or within normal ranges.

Histopathological examination is nonspecific: It is characterized by dermal edema, perivascular and periadnexal lympho-histiocytic infiltrate, with more or less numerous mast cells, and dilated lymphatic vessels. Granulomas are sometimes present. Sebaceous gland hyperplasia may be observed in patients with previous or coexisting acne or rosacea.\[[@ref12]\]

Biopsy for histopathological examination must be always performed because Morbihan syndrome enters into differential clinical diagnosis with metastases to the periorbital area. Other differential diagnoses include congenital, infectious, inflammatory, neoplastic, and miscellaneous diseases \[[Table 1](#T1){ref-type="table"}\].\[[@ref9]\] Furthermore, barbiturates,\[[@ref13]\] chlorpromazine,\[[@ref14]\] diltiazem,\[[@ref15]\] and even isotretinoin\[[@ref16]\] can induce clinical manifestations similar to Morbihan syndrome.
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Several systemic drugs were used for the therapy of Morbihan syndrome. They include thalidomide,\[[@ref17]\] clofazimine,\[[@ref18]\] tetracyclines,\[[@ref19]\] and corticosteroids.\[[@ref8]\] However, only isotretinoin,\[[@ref20][@ref21]\] alone or associated with ketotifen,\[[@ref12]\] seems to be really effective. It has to be used at high doses and for long periods of time. As previously mentioned, in our patient, isotretinoin, despite the long duration of the therapy (26 weeks), was ineffective. The literature review allows us to state that in 15-20% of patients oral isotretinoin is ineffective: In these patients, the clinical course of Morbihan syndrome is uncertain, the disease can become chronic or can relapse. Surgical therapy\[[@ref22]\] and CO2 laser\[[@ref23]\] have been also advocated.

**Source of Support:** Nil

**Conflict of Interest:** None declared
